ArticleBMJ open2026
Intravenous dexmedetomidine dose and analgesic outcomes after femoral nerve block for anterior cruciate ligament reconstruction: a single-centre retrospective cohort study in China.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo retrospectively examine the association between different intravenous dexmedetomidine (DEX) doses and analgesic outcomes, safety events and 6-month functional outcomes after femoral nerve block (FNB) in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction and to explore the dose range associated with analgesic outcomes and observed safety events. DESIGN, SETTING AND
participantsIn this single-centre retrospective cohort study, patients who underwent arthroscopic ACL reconstruction with FNB at Peking University Third Hospital between January and December 2024 were analysed. After 1:1:1:1 matching on a generalised propensity score (calliper 0.02 per dimension), the matched cohort comprised 148 patients (37 per group): R (ropivacaine only), RD 0.5 (ropivacaine plus intravenous DEX 0.5 μg/kg), RD 0.75 (0.75 μg/kg) and RD 1 (1 μg/kg). The primary outcome was the duration of analgesia. Secondary outcomes included resting and dynamic pain scores within 48 hours, rescue analgesic consumption, safety outcomes and 6-month sensory/muscle strength assessments. A 4-parameter logistic (4PL) model was used to examine the dose-response pattern.
resultsAll DEX groups were associated with longer analgesic duration than group R. RD 0.75 and RD 1 had longer durations than RD 0.5 (p<0.05), with no significant difference between RD 0.75 and RD 1 (p>0.05). An exploratory 4PL sigmoidal model suggested a non-linear dose-response pattern for analgesic duration (R²=0.2545, residual SE=10.29), with a plateau phase at 0.75 μg/kg. RD 0.75 and RD 1 had significantly lower 48-hour pain AUC. Postoperative 48-hour opioid consumption showed an overall between-group difference, but no pairwise comparison remained statistically significant after Bonferroni correction. Only RD 1 showed a significantly higher bradycardia incidence than R; most patients in the DEX groups showed mild-to-moderate sedation and hypoxaemia was uncommon. No 6-month sensory deficits or intergroup muscle strength differences were detected within this cohort.
conclusionIntravenous DEX (0.5-1 μg/kg) was associated with prolonged early postoperative analgesia in ACL reconstruction. Within this cohort, the 0.75 μg/kg dose showed analgesic results similar to 1 μg/kg, with a numerically lower bradycardia incidence. No neurological deficits, sensory abnormalities or between-group differences in muscle strength and motor recovery were detected at 6 months within this cohort. These findings are based on a retrospective design and reflect associations rather than causal relationships, requiring verification by prospective randomised controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.